Parnassus Investments CA bought a new stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 2,700,000 shares of the biopharmaceutical company’s stock, valued at approximately $172,098,000. Parnassus Investments CA owned about 0.16% of Bristol-Myers Squibb at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in the stock. Tradewinds Capital Management LLC increased its holdings in Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares during the period. Atlantic Trust LLC bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter worth about $111,000. American National Bank grew its holdings in shares of Bristol-Myers Squibb by 11.7% in the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 225 shares during the last quarter. Blue Chip Partners Inc. grew its holdings in shares of Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares during the last quarter. Finally, BDO Wealth Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter worth about $123,000. Hedge funds and other institutional investors own 69.67% of the company’s stock.
A number of brokerages have commented on BMY. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Wednesday, October 25th. BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 26th. Vetr downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 target price on the stock. in a research report on Friday, December 22nd. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Jefferies Group downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 target price on the stock. in a research report on Monday, October 16th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $65.05.
In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at $585,033.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Co (NYSE BMY) opened at $62.81 on Friday. Bristol-Myers Squibb Co has a 52 week low of $46.01 and a 52 week high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The firm has a market cap of $102,244.66, a price-to-earnings ratio of 24.73, a P/E/G ratio of 2.29 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same period in the prior year, the business earned $0.77 EPS. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. research analysts anticipate that Bristol-Myers Squibb Co will post 2.99 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be issued a dividend of $0.40 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 62.99%.
ILLEGAL ACTIVITY WARNING: “Parnassus Investments CA Purchases Shares of 2,700,000 Bristol-Myers Squibb Co (NYSE:BMY)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/13/parnassus-investments-ca-acquires-shares-of-2700000-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.